Details of the Drug

General Information of Drug (ID: DMMF5IE)

Drug Name
GS-9883
Synonyms
Bictegravir; Bictegravir (USAN/INN); Bictegravir [INN]; Bictegravir [USAN:INN]; SB18851; SOLUWJRYJLAZCX-LYOVBCGYSA-N; (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide; 1611493-60-7; 8GB79LOJ07; BCP25703; BDBM330048; CHEMBL3989866; DB11799; GS 9883; GS-9883; GS-9883-01; SCHEMBL15914278; UNII-8GB79LOJ07
Affected Organisms
Human Immunodeficiency Virus
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 449.4
Logarithm of the Partition Coefficient (xlogp) 2.7
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
Absorption
The drug is rapidly absorbed []
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2-4 h []
Elimination
About 1% of the bictegravir dose is excreted from the urine in unchanged form [1]
Half-life
The concentration or amount of drug in body reduced by one-half in 17.3 hours []
Metabolism
The drug is metabolized via the liver []
Vd
The volume of distribution (Vd) of drug is 0.2 L/kg [1]
Chemical Identifiers
Formula
C21H18F3N3O5
IUPAC Name
(1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide
Canonical SMILES
C1CC2CC1N3C(O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F
InChI
InChI=1S/C21H18F3N3O5/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30)/t10-,11+,16+/m0/s1
InChIKey
SOLUWJRYJLAZCX-LYOVBCGYSA-N
Cross-matching ID
PubChem CID
90311989
ChEBI ID
CHEMBL3989866
CAS Number
1611493-60-7
UNII
8GB79LOJ07
DrugBank ID
DB11799
INTEDE ID
DR0212
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [2]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1CInfected Adults
2 Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2019 Nov;55(11):669-682.